Mode of action for linear peptide inhibitors of HIV-1 gp120 interactions.
D000494:Allosteric Regulation; D000818:Animals; D019380:Anti-HIV Agents / Q000737:chemistry* / Q000378:metabolism; D000911:Antibodies, Monoclonal / Q000378:metabolism; D001666:Binding Sites, Antibody; D065100:CCR5 Receptor Antagonists; D015704:CD4 Antigens / Q000378:metabolism; D002460:Cell Line; D004285:Dogs; D015699:HIV Envelope Protein gp120 / Q000378:metabolism*; D015497:HIV-1 / Q000378:metabolism* / Q000472:pathogenicity; D006801:Humans; D009842:Oligopeptides / Q000138:chemical synthesis / Q000737:chemistry* / Q000378:metabolism; D011485:Protein Binding; D019713:Receptors, CCR5 / Q000378:metabolism; D012995:Solubility; D020349:Surface Plasmon Resonance; D013601:T-Lymphocytes / Q000378:metabolism / Q000821:virology
D019380:Anti-HIV Agents; D000911:Antibodies, Monoclonal; D065100:CCR5 Receptor Antagonists; D015704:CD4 Antigens; D015699:HIV Envelope Protein gp120; D009842:Oligopeptides; D019713:Receptors, CCR5